T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2B |
| 2 |
Sea Limited
SE
|
+$1.34B |
| 3 |
Morgan Stanley
MS
|
+$1.23B |
| 4 |
Incyte
INCY
|
+$1.05B |
| 5 |
Ross Stores
ROST
|
+$968M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.05B |
| 2 |
VMW
VMware, Inc
VMW
|
+$1.5B |
| 3 |
Visa
V
|
+$1.16B |
| 4 |
JPMorgan Chase
JPM
|
+$1.13B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.01% |
| 2 | Healthcare | 17.6% |
| 3 | Consumer Discretionary | 14.37% |
| 4 | Financials | 11.89% |
| 5 | Communication Services | 10.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CXO
226
DELISTED
CONCHO RESOURCES INC.
CXO
| $733M | 0.09% |
14,224,226
-8,493,221
| -37% | -$469M |
|
227
Avery Dennison
AVY
$13.5B
| $724M | 0.09% |
6,346,378
+16,437
| +0.3% | +$1.81M |
|
228
Skyworks Solutions
SWKS
$10.6B
| $723M | 0.09% |
5,656,517
-46,463
| -0.8% | -$5.15M |
|
|
GLIBA
229
DELISTED
GCI Liberty, Inc. Class A Common Stock (DE)
GLIBA
| $721M | 0.09% |
10,144,477
-409,706
| -4% | -$26.3M |
|
230
AstraZeneca
AZN
$246B
| $720M | 0.09% |
6,805,063
+514,307
| +8% | +$53.1M |
|
231
GSK
GSK
$101B
| $719M | 0.09% |
14,098,746
+366,244
| +3% | +$18.8M |
|
|
PFPT
232
DELISTED
Proofpoint, Inc.
PFPT
| $718M | 0.09% |
6,461,323
-1,311,750
| -17% | -$150M |
|
233
EOG Resources
EOG
$74.7B
| $716M | 0.09% |
14,124,545
-1,928,234
| -12% | -$93.4M |
|
|
PRAH
234
DELISTED
PRA Health Sciences, Inc.
PRAH
| $714M | 0.09% |
7,343,163
-38,474
| -0.5% | -$3.58M |
|
235
HubSpot
HUBS
$10.6B
| $705M | 0.09% |
3,142,043
+2,046,818
| +187% | +$368M |
|
236
Regeneron Pharmaceuticals
REGN
$83.1B
| $701M | 0.09% |
1,123,386
+116,053
| +12% | +$65.9M |
|
237
Charter Communications
CHTR
$18.1B
| $691M | 0.09% |
1,355,196
+64,339
| +5% | +$32.6M |
|
238
T-Mobile US
TMUS
$194B
| $691M | 0.09% |
6,633,970
+1,634,677
| +33% | +$157M |
|
239
ConocoPhillips
COP
$151B
| $687M | 0.09% |
16,348,634
-1,693,935
| -9% | -$68.5M |
|
240
Exelon
EXC
$46.9B
| $685M | 0.09% |
26,453,372
+23,662,168
| +848% | +$628M |
|
241
Capital One
COF
$136B
| $681M | 0.09% |
10,882,808
+7,917,593
| +267% | +$493M |
|
242
Gilead Sciences
GILD
$170B
| $681M | 0.09% |
8,846,587
-2,233,872
| -20% | -$171M |
|
243
TAL Education Group
TAL
$6.43B
| $675M | 0.08% |
9,870,892
+785,495
| +9% | +$44.9M |
|
244
MarketAxess Holdings
MKTX
$5.72B
| $674M | 0.08% |
1,345,551
-256,839
| -16% | -$120M |
|
245
Corning
GLW
$143B
| $671M | 0.08% |
25,918,545
+975,335
| +4% | +$22.1M |
|
246
Descartes Systems
DSGX
$6.46B
| $671M | 0.08% |
12,686,270
-38,228
| -0.3% | -$1.7M |
|
247
Mondelez International
MDLZ
$80.5B
| $669M | 0.08% |
13,086,328
-1,255,977
| -9% | -$64.5M |
|
248
Edison International
EIX
$27.4B
| $668M | 0.08% |
12,300,648
-7,764,782
| -39% | -$447M |
|
|
ETFC
249
DELISTED
E*Trade Financial Corporation
ETFC
| $667M | 0.08% |
13,412,459
+1,083,550
| +9% | +$46.7M |
|
250
Nike
NKE
$60.6B
| $664M | 0.08% |
6,769,434
-4,624,520
| -41% | -$427M |
|
Similar funds
T. Rowe Price Associates's Q2 2020 Portfolio in Review
As of Q2 2020, T. Rowe Price Associates held 2,591 positions worth $795B, up 26% from $632B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
T. Rowe Price Associates's Q2 2020 filing shows 79 new, 1,096 increased, 1,255 reduced and 100 closed positions. Its largest new stake was Vroom Inc: 200,362 shares worth $797M. The largest sale was Boeing, an estimated $2.05B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2020 buy was Vroom Inc: 200,362 shares worth $797M.
- T. Rowe Price Associates added most to Microsoft in Q2 2020, an estimated $2B increase.
- T. Rowe Price Associates's biggest Q2 2020 reduction was Boeing, cutting an estimated $2.05B.
- T. Rowe Price Associates fully exited Raytheon Company in Q2 2020, selling an estimated $1.01B.
- T. Rowe Price Associates's ten largest holdings make up 25% of its $795B portfolio in Q2 2020.
- T. Rowe Price Associates opened 79 new positions and closed 100 in Q2 2020.
- T. Rowe Price Associates's portfolio value rose 26% quarter-over-quarter to $795B.
Based on T. Rowe Price Associates's 13F filing for Q2 2020, filed 14 Aug 2020.